Search results
Results from the WOW.Com Content Network
The presentation of patient with SPCD can be incredibly varied, from asymptomatic to lethal cardiac manifestations. [5] Early cases were reported with liver dysfunction, muscular findings (weakness and underdevelopment), hypoketotic hypoglycemia, cardiomegaly, cardiomyopathy and marked carnitine deficiency in plasma and tissues, combined with increased excretion in urine. [5]
Carnitine-acylcarnitine translocase deficiency has an autosomal recessive pattern of inheritance. Carnitine-acylcarnitine translocase deficiency is a rare, autosomal recessive metabolic disorder that prevents the body from converting long-chain fatty acids into energy, particularly during periods without food. [ 1 ]
Carnitine palmitoyltransferase I deficiency; Carnitine-acylcarnitine translocase deficiency; Carnosinemia; Caroli disease; Castleman disease; Catamenial pneumothorax; Catecholaminergic polymorphic ventricular tachycardia; CD55 deficiency; CDKL5 deficiency disorder; Cenani–Lenz syndactylism; Center of expertise for rare diseases; Cerebral ...
SLC22A5 is a membrane transport protein associated with primary carnitine deficiency.This protein is involved in the active cellular uptake of carnitine.It acts a symporter, moving sodium ions and other organic cations across the membrane along with carnitine.
57279 Ensembl ENSG00000178537 ENSMUSG00000032602 UniProt O43772 Q9Z2Z6 RefSeq (mRNA) NM_000387 NM_020520 RefSeq (protein) NP_000378 NP_065266 Location (UCSC) Chr 3: 48.86 – 48.9 Mb Chr 9: 108.54 – 108.56 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 Identifiers Symbol SLC25A20 Alt. symbols CACT NCBI gene ...
L-Carnitine, acetyl-l-carnitine, and propionyl-l-carnitine are available in dietary supplement pills or powders, with a daily amount of 0.5 to 1 g considered to be safe. [1] [3] It is also a drug approved by the Food and Drug Administration to treat primary and certain secondary carnitine-deficiency syndromes secondary to inherited diseases. [1 ...
Carnitine, a natural substance acquired mostly through the diet, is used by cells to process fats and produce energy. People with this disorder have a faulty enzyme, carnitine palmitoyltransferase I , that prevents these long-chain fatty acids from being transported into the mitochondria to be broken down.
Carnitine palmitoyltransferase II deficiency, sometimes shortened to CPT-II or CPT2, is an autosomal recessively inherited genetic metabolic disorder characterized by an enzymatic defect that prevents long-chain fatty acids from being transported into the mitochondria for utilization as an energy source. The disorder presents in one of three ...